New World Evidence Data Market, By Component (Dataset (Claims, Clinical, Pharmacy, and Patient) and Services), By Therapeutic Area (Oncology, Cardiovascular, and Immunology), By End-User (Pharmaceuticals, Medical Devices, Payers, and Providers), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2034

Report Code: PMI255719 | Publish Date: January 2024 | No. of Pages: 178

Global New World Evidence Market Companies

  • IQVIA Holdings, Inc.
  • International Business Machines Corporation
  • Syneos Health, Inc.
  • ICON Public Limited Company
  • Pharmaceutical Product Development LLC
  • Optum, Inc.
  • Cognizant Technology Solutions Corp.
  • SAS Institute, Inc.
  • Flatiron Health, Inc.

Recent news:

  • The Real-World Evidence Transparency Initiative was introduced in October 2021 by the Professional Society for Health Economics and Outcomes Research (ISPOR), in collaboration with the International Society of Pharmaco epidemiology, the Duke-Margolis Centre for Health Policy, and the National Pharmaceutical Council. Based on benchmarking study on real-world evidence (RWE) conducted by Deloitte, there is an increasing adoption of RWD and RWE throughout the product life cycle. Biopharma companies, for example, incorporated RWE into regulatory submissions more frequently than only fulfilling post-marketing requirements. During the COVID-19 pandemic, biopharma companies were able to develop and swiftly introduce novel vaccines and therapies for this highly contagious disease to the market with the use of RWD/E (Real World Data Evidence).
  • To facilitate clinical teams more easily, IQVIATM debuted two of its features in September 2019. The top five pharmaceutical companies currently use the features that were tested and co-designed.